DCT

1:26-cv-00623

Pfizer Inc v. Alkem Laboratories Ltd

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 1:26-cv-00623, D. Del., 05/29/2026
  • Venue Allegations: Venue is asserted based on Defendant Alkem being a foreign corporation, which may be sued in any judicial district, and its subjection to personal jurisdiction in Delaware. The complaint also alleges that because Plaintiff Pfizer Inc. is a Delaware corporation, it suffers injury from Alkem's actions within the state.
  • Core Dispute: Plaintiffs allege that Defendant's submission of an Abbreviated New Drug Application (ANDA) to the FDA for a generic version of the cancer drug Inlyta® (axitinib) constitutes an act of infringement of a patent covering specific crystalline forms of the drug's active ingredient.
  • Technical Context: The lawsuit concerns specific crystalline structures (polymorphs) of an active pharmaceutical ingredient, a field critical to drug development for ensuring product stability, manufacturability, and consistent bioavailability.
  • Key Procedural History: This action arises under the Hatch-Waxman Act, triggered by Alkem's submission of ANDA No. 221501 with a Paragraph IV certification. Alkem notified Pfizer of its filing via a letter dated April 17, 2026, asserting that its generic product would not infringe U.S. Patent No. 8,791,140 or that the patent is invalid. The complaint notes that the parties corresponded but failed to agree on terms for Pfizer to review Alkem's confidential ANDA information.

Case Timeline

Date Event
2007-04-05 '140 Patent Priority Date
2012-01-27 FDA Approval for Inlyta®
2014-07-29 '140 Patent Issue Date
2026-04-17 Alkem's Notice Letter to Pfizer
2026-05-29 Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 8,791,140 - "Crystalline Forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazole Suitable for the Treatment of Abnormal Cell Growth in Mammals" (Issued July 29, 2014)

The Invention Explained

  • Problem Addressed: The patent's background explains that the same chemical compound can exist in different solid-state forms, known as polymorphs, each with unique physical properties (e.g., stability, solubility, flow characteristics) '140 Patent, col. 2:11-19 For pharmaceutical manufacturing, it is highly desirable to identify and consistently produce a specific, stable polymorph to ensure reliable formulation, safety, and efficacy '140 Patent, col. 2:31-39
  • The Patented Solution: The invention identifies and characterizes several novel crystalline (polymorphic) and amorphous forms of the active pharmaceutical ingredient axitinib (referred to as "Compound 1") '140 Patent, abstract The patent uses analytical techniques, primarily powder X-ray diffraction (PXRD), to define these distinct forms by their unique structural fingerprints, such as specific peak locations in a diffraction pattern '140 Patent, col. 4:50-65 This allows for the selection and preparation of a specific form with advantageous properties for use in a pharmaceutical product.
  • Technical Importance: Identifying and claiming a specific, stable crystalline form of a drug substance is a critical step in pharmaceutical development, as it helps ensure consistent product quality, shelf life, and bioavailability. '140 Patent, col. 2:39-49

Key Claims at a Glance

  • The complaint asserts infringement of claims 1 through 6 of the '140 patent Compl. ¶34
  • Independent claim 1, provided as an example in the complaint, contains the following essential elements Compl. ¶32:
    • [a] crystalline form of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl] indazole,
    • wherein said crystalline form has a powder X-ray diffraction pattern comprising a peak at diffraction angle (20) of 6.0±0.1
    • and further comprising at least one peak at diffraction angle (20) selected from 11.5±0.1, 21.0±0.1 and 26.9±0.1.

III. The Accused Instrumentality

Product Identification

The accused instrumentality is "Alkem's ANDA Product," a generic version of axitinib tablets (1 mg and 5 mg) for which Alkem seeks FDA approval through Abbreviated New Drug Application No. 221501 Compl. ¶¶1-2 Under the Hatch-Waxman Act, the act of infringement is the submission of the ANDA itself for the purpose of marketing a drug claimed in a patent before its expiration Compl. ¶25

Functionality and Market Context

Alkem's ANDA Product is intended to be a generic equivalent to Pfizer's Inlyta®, a drug approved for the treatment of advanced renal cell carcinoma Compl. ¶17 By filing a Paragraph IV certification, Alkem is challenging the '140 patent's validity and/or applicability to its product, seeking to enter the market before the patent's expiration Compl. ¶21 The complaint alleges that Alkem intends to commercially manufacture, use, and sell its ANDA Product immediately upon receiving FDA approval Compl. ¶36

IV. Analysis of Infringement Allegations

The complaint's infringement theory is that Alkem's ANDA, filed to obtain approval for its generic axitinib product, is a technical act of infringement under 35 U.S.C. § 271(e)(2) Compl. ¶25 The core factual allegation, made on information and belief, is that the drug substance in Alkem's ANDA Product is the specific crystalline form of axitinib protected by the '140 patent Compl. ¶33 No probative visual evidence provided in complaint.

'140 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
[a] crystalline form of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl] indazole The complaint alleges, upon information and belief, that Alkem's ANDA Product contains a crystalline form of this specific chemical compound. ¶33 col. 2:20-30
wherein said crystalline form has a powder X-ray diffraction pattern comprising a peak at diffraction angle (20) of 6.0±0.1 The complaint alleges, upon information and belief, that the crystalline form in Alkem's ANDA Product exhibits this characteristic peak in its PXRD pattern. ¶33 col. 4:50-54
and further comprising at least one peak at diffraction angle (20) selected from 11.5±0.1, 21.0±0.1 and 26.9±0.1. The complaint alleges, upon information and belief, that the crystalline form in Alkem's ANDA Product further exhibits at least one of these additional characteristic peaks in its PXRD pattern. ¶33 col. 4:50-61

Identified Points of Contention

  • Factual Question: Since the allegations are made on "information and belief" prior to discovery, a central point of contention will be a factual one: what do the characterization data (e.g., PXRD) for Alkem's ANDA Product actually show? The case will likely hinge on whether the data from Alkem's product sample falls within the specific analytical parameters defined by the claims.
  • Scope Question: The dispute may raise the question of how to interpret the numerical ranges in the claims. A key issue could be whether a peak measured at the margin of the "±0.1" range (e.g., 6.11 degrees 2-theta) meets the claim limitation, a common point of dispute in polymorph litigation.

V. Key Claim Terms for Construction

  • The Term: "crystalline form"

    • Context and Importance: This term is foundational to the patent, as the claims are directed to a specific solid-state form of a compound, not the compound itself. Its construction will determine the scope of what physical materials are covered by the claims.
    • Intrinsic Evidence for Interpretation:
      • Evidence for a Broader Interpretation: The patent provides a standard definition: "The term 'crystalline' refers to any solid substance exhibiting three-dimensional order" '140 Patent, col. 14:20-22 This supports a broad, conventional understanding of the term.
      • Evidence for a Narrower Interpretation: A defendant might argue that a product containing a mixture of polymorphs is not "a crystalline form" in the singular, but rather a composition of multiple forms. The patent itself distinguishes numerous distinct polymorphic forms, which could be used to argue that the claims to a single form require a high degree of polymorphic purity.

  • The Term: "...a powder X-ray diffraction pattern comprising a peak at diffraction angle (20) of... ±0.1"

    • Context and Importance: Infringement will be determined by comparing Alkem's PXRD data to the numerical values in the claims. The interpretation of the "±0.1" range is therefore critical to determining whether a match exists.
    • Intrinsic Evidence for Interpretation:
      • Evidence for a Broader Interpretation: The specification explicitly acknowledges instrumental variability, stating that "one skilled in the art will appreciate that the peak positions (20) will show some variability, typically as much as 0.1 to 0.2 degrees" '140 Patent, col. 12:32-36 Plaintiffs may cite this language to argue the "±0.1" range should be interpreted to account for standard measurement tolerances.
      • Evidence for a Narrower Interpretation: A defendant could argue for a strict application of the "±0.1" range recited in the claim. The specification also discusses how experimental errors, such as sample height differences, can lead to much larger peak shifts, which a defendant might use to argue that without precise calibration and methodology, any data comparison is unreliable '140 Patent, col. 16:5-10

VI. Other Allegations

  • Indirect Infringement: The complaint alleges that Alkem will actively induce infringement upon FDA approval by marketing and selling its product, thereby encouraging acts of direct infringement (e.g., use by patients and physicians) with knowledge of the '140 patent Compl. ¶¶38-39
  • Willful Infringement: Willfulness is alleged based on Alkem's "full knowledge of the '140 patent," evidenced by its filing of a Paragraph IV certification specifically challenging the patent listed in the FDA's Orange Book Compl. ¶42 Compl. ¶21 The complaint further alleges Alkem acted "without a reasonable basis for believing that Alkem would not be liable for infringing" Compl. ¶42

VII. Analyst's Conclusion: Key Questions for the Case

  1. A core question will be one of physical identity: once discovery is conducted, will the active pharmaceutical ingredient in Alkem's ANDA Product possess the specific crystalline structure defined by the powder X-ray diffraction peaks recited in the asserted claims of the '140 patent?
  2. A second key issue will be one of patent validity: as signaled by its Paragraph IV certification, Alkem has asserted that the '140 patent is invalid Compl. ¶21 The case will therefore likely involve a defensive argument from Alkem that the claimed crystalline form was obvious, not novel, or inadequately described in the patent, shifting the focus from infringement to the patent's own strength.
  3. A determinative subsidiary question will be one of definitional precision: how will the court construe the numerical claim limitation "±0.1" in the context of PXRD analysis? The outcome of this construction, informed by the patent's own statements on instrumental variability, could decide the infringement question if Alkem's product data lies at the edge of the claimed range.
Loading Complaint